Nutrition with non-viable Bifidobacterium and non-digestible oligosaccharide

Patent metadata

Field	Value
Publication number	US-9456629-B2
Application number	US-66478508-A
Country	US
Kind code	B2
Filing date	Jun 13, 2008
Priority date	Jun 15, 2007
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

An infant and/or toddler nutrition comprising non-viable Bifidobacterium breve and a non-digestible oligosaccharide and its use are disclosed.

First claim

The invention claimed is:

1. A method for treating and/or reducing the occurrence of an allergic disease or condition in an infant or toddler subject, comprising feeding to the subject a nutritional composition which has a pH between 5.5 and 8 and which comprises:
(a) a first and a second non-digestible oligosaccharide each having a degree of polymerization of 2 to 200, wherein the first non-digestible oligosaccharide is a transgalacto-oligosaccharide and the second non-digestible oligosaccharide is a fructo-oligosaccharide;
(b) non-viable Bifidobacterium breve bacteria from strain M-16V or I-2219 in an amount equivalent to 10 6 to 10 13 viable colony forming units (cfu) per gram dry weight of the nutritional composition, wherein viable Bifidobacterium breve bacteria are present in an amount that is below their detection limit as measured by plating; and
(c) cow's milk protein.

2. The method according to claim 1 wherein the allergy is a food allergy.

3. The method according to claim 1 , wherein the nutritional composition is in liquid form.

4. The method according to claim 1 , wherein the cow's milk protein is hydrolyzed.

5. The method according to claim 1 , wherein the nutritional composition is not fermented.

6. The method according to claim 1 , wherein the weight ratio of the first oligosaccharide to the second oligosaccharide is from 19/1 to 1/19.

7. The method according to claim 1 , wherein the nutritional composition comprises 0.5 to 10 wt. % non-digestible oligosaccharide based on dry weight of the nutritional composition.

8. The method according to claim 1 wherein the nutritional composition further comprises eicosapentaenoic acid and/or docosahexaenoic acid, and/or arachidonic acid.

9. The method according to claim 1 wherein the nutritional composition further comprises between 5 and 50 energy % lipid, between 5 and 50 energy % protein, and between 15 and 90 energy % carbohydrate.

10. The method according to claim 1 wherein the degree of polymerization of the first oligosaccharide is at least 5 monosaccharide units less than the degree of polymerization of said second oligosaccharide.

11. The method according to claim 1 , wherein the non-viable Bifidobacterium breve are produced by inactivating viable Bifidobacterium breve using heat treatment.

Assignees

• Hougee Sander
• Vriesema Adrianus Johannes Maria
• Garssen Johan
• Knol Jan
• Nutricia Nv

Inventors

• Hougee Sander
• Vriesema Adrianus Johannes Maria
• Garssen Johan
• Knol Jan

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title